Simple Summary
This prospective study evaluated the clinical utility of sequential circulating tumor DNA (ctDNA) monitoring in 52 patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. ctDNA was detected in 98.1% of patients at baseline, showing a 74.7% concordance with tumor tissue genotyping. Higher baseline ctDNA levels were associated with poor prognostic features such as elevated LDH, older age, and higher IPI scores. A ≥2-log reduction in ctDNA after three treatment cycles was significantly associated with improved overall survival but not progression-free survival. Integration of interim ctDNA changes with PET/CT response improved prognostic accuracy, particularly in patients with partial metabolic responses. Notably, patients with both ctDNA and PET/CT positivity at interim had significantly worse survival outcomes. The study highlights ctDNA as a feasible non-invasive biomarker for tumor genotyping and dynamic risk stratification in DLBCL. It also emphasizes the need for highly sensitive ctDNA assays, especially for predicting CNS relapse. Overall, combining ctDNA dynamics with imaging could enhance individualized treatment strategies in DLBCL.
Abstract
Background/Objectives: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for non-invasive tumor monitoring in diffuse large B-cell lymphoma (DLBCL). Methods: In this study, 52 patients with newly diagnosed advanced-stage DLBCL treated with R-CHOP underwent serial ctDNA analysis at baseline, interim (after three cycles), and end of treatment. The prognostic significance of ctDNA dynamics was evaluated, and its predictive value was compared with the PET/CT response. Results: Targeted next-generation sequencing revealed baseline ctDNA in 98.1% of patients, with 74.7% concordance to tumor tissue genotyping. Higher baseline ctDNA levels correlated with elevated LDH, older age, and high IPI scores. A ≥2-log reduction in ctDNA at interim was significantly associated with improved overall survival (p = 0.004), though not with progression-free survival. Notably, combining interim ctDNA dynamics with PET/CT results enhanced the predictive accuracy for treatment outcomes, particularly among patients with partial metabolic responses. Conclusions: These findings support the clinical utility of ctDNA for dynamic risk assessment in DLBCL, and suggest that integrating ctDNA with imaging biomarkers may guide more personalized therapeutic strategies. Further validation using highly sensitive ctDNA assays is warranted to optimize its role in routine clinical practice.